Highlights Corvus Pharmaceuticals, Inc.

Equities

CRVS

US2210151005

Real-time Estimate Cboe BZX Other stock markets 16:03:08 09/05/2024 BST			5-day change	1st Jan Change
2.19 ^USD	+11.73%		+23.12%	+21.02%

05-07	Corvus Pharmaceuticals Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing	MT
05-07	Oppenheimer Adjusts Price Target on Corvus Pharmaceuticals to $8 From $7, Maintains Outperform Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Corvus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	04-30	MT
Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	04-09	CI
Corvus Pharmaceuticals to Start Phase 1 Study of Atopic Dermatitis Treatment in Q2	03-19	MT
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-19	CI
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	02-12	CI
Corvus Pharmaceuticals Shares Rise on Orphan Drug Designation	02-08	DJ
Corvus Pharmaceuticals, Inc. Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial	12-09	CI
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases	11-01	CI
Corvus Pharmaceuticals, Inc. Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma	07/09/23	CI
Corvus Completes FDA Meeting on Plans to Launch Phase 3 Cancer Trial; Shares Jump After-Hours	06/09/23	MT
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23	CI
Corvus Pharmaceuticals, Inc. Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference	29/06/23	CI
Corvus Pharmaceuticals, Inc. Presents New Cpi-818 Interim Data At the International Conference on Malignant Lymphoma	15/06/23	CI
CORVUS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	08/05/23	AQ
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	08/05/23	CI
Corvus Pharmaceuticals, Inc. Presents New CPI-818 Data Demonstrating the Potential of Itk Inhibition as A Treatment for Solid and Hematologic Cancers	17/04/23	CI
Corvus Pharmaceuticals, Inc. Announces CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma	03/04/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Corvus Pharmaceuticals, Inc.

Equities

CRVS

US2210151005

Highlights

Filters